

# SVS Aubrey Global Emerging Markets Fund



FACTSHEET: April 2024

## KEY FACTS

### Investment Objective


The Fund aims to achieve capital growth over the long term (5 years plus) and will invest at least 95% in shares of emerging market companies. The Investment Manager's focus is on growth companies expected to deliver increasing revenue and profit from the expansion of their business over the medium to long term. As part of its investment process, the Investment Manager integrates environmental, social and governance ("ESG") factors into its routine analysis.

### Fund Information

FUND NAME	SVS Aubrey Global Emerging Markets Fund	INCEPTION DATE	12th May 2021
LEGAL FORM	Open-Ended Investment Company (OEIC)	FUND SIZE	£10.1m
UMBRELLA	SVS Aubrey Capital Management Investment Funds	STRATEGY SIZE	£474.1m
ADMINISTRATOR	Evelyn Partners Fund Solutions Limited	INDEX	MSCI TR Net Emerging Markets GBP
DOMICILE	UK	PRICING FREQUENCY	Daily
CURRENCIES	GBP, USD, EUR	MANAGERS	Andrew Dalrymple, John Ewart, Rob Brewis

## NET PERFORMANCE

NET PERFORMANCE % AS AT 30/04/2024	1M	3M	6M	YTD	1Y	Inception
SVS Aubrey Global Emerging Markets Fund	-0.3	8.0	16.8	6.9	17.2	-15.4
MSCI TR Net Emerging Markets Index	1.4	9.7	12.1	4.9	10.5	-3.4



— SVS Aubrey GEM -15.4%  
— MSCI EM Index -3.4%

Source: Aubrey Capital Management, MSCI and Evelyn Partners Fund Solutions Limited.

All figures are presented net of fees in GBP and calculated using the B Accumulation share class. MSCI Emerging Markets Index is used for comparative purposes only. Investment returns may increase or decrease as a result of currency fluctuations. Past performance is no guarantee of future results. The ACD has selected this comparator benchmark as it believes this benchmark best reflects the Fund's asset allocation.


## PORTFOLIO BREAKDOWN

### Top 10 Positions


Company	% of Holding
Varun Beverages	5.3
Zomato	5.0
Macrotech	4.8
Trip.com	4.2
Trent	3.9
Indian Hotels	3.8
DLF	3.7
MakeMyTrip	3.7
Apollo Hospitals	3.5
Mercadolibre	3.4
Number of Holdings	32

The securities identified and described do not represent all of the securities purchased, sold or recommended for client accounts. The reader should not assume that an investment in the securities identified was or will be profitable.

### Sector Allocation



### Geographic Allocation



### MARKETING COMMUNICATION



## MANAGER'S COMMENTARY

The Fund has had a quiet month with the net asset value -0.3% lower which is slightly behind the 1.4% rise in the MSCI Emerging Markets Index.

Although there was little in the way of tangible good news, there were signs of a revival in China with the Hang Seng China Enterprises Index rising by 8%. The economy still appears to be growing, and to be fair, fear and despondency towards China had reached something of a peak at the end of February and so a rebound was well overdue.

Only two of the portfolio companies produced results, with **Proya Cosmetics** announcing a very good set of figures for 2023 which were comfortably ahead of expectations. Sales rose by 39.5% with net profit no less than 46.1% higher. For the current year the company expect sales growth of over 20% and reported that several new brands had launched very successfully. The shares ended the month 14.1% higher following this news.

Less helpfully, results from **New Oriental Education** were less well received. While sales growth was exceptionally good, driven by new business initiatives and the online subsidiary East Buy, margins contracted somewhat due to an accelerated expansion of learning centres, and extra investment into East Buy. The stock ended the month 11% lower, but the outlook for 2024 is still very good, and in our view the shares remain attractively valued.

Travel still seems to be an area of strength in China and with hotel and rail bookings reported as very strong ahead of the Labour Day holidays, **Trip.com** gained 10%, while **Tencent Music**, the nearest equivalent to Spotify in China rose by 12.2%. During the month we bought new positions in **Midea**, China's leading maker of household appliances, and **DiDi**, which is China's massively dominant ride hailing App. This was done by disposing of **Raia Drogasil** in Brazil, and **Femsa** in Mexico, neither of which looked as promising.

The Indian market was barely changed in April, and the Fund's holdings were somewhat mixed. Most Indian companies have March year ends and so year end reporting is in full swing, and indeed is providing great encouragement. **Macrotech Developers** comfortably exceeded 2024 estimates and forecast sales growth of 20% for 2025. **Trent**, the Tata Group retail enterprise reported revenue growth of 53% in the final quarter of the year led by 10% same stores sales growth as well as a massive store expansion. Much improved margins translated into an 86% growth in net profit. Shares in **Macrotech** gained 9.0% in the month, while **Trent** ended 11.7% higher. **Indian Hotels** also reported a set of highly satisfactory figures, although this news was met with a little profit taking, while **ICICI Bank** rose 4.2% following their earnings report which revealed a favourable loan mix, stable net interest margins, and good cost control. Best of all, however, was **Eicher Motors** the maker of Royal Enfield motorcycles. A good set of sales figures for March accompanied by several broker upgrades sent the shares 14.4% higher.

It was a more difficult period in Latin America, where Mexico and Brazil were perhaps worse affected by a likely delay in interest rate reductions by the Federal Reserve. Both markets were lower this month, and the currencies were weak. In Mexico, first quarter results from **Alsea** (restaurants), were adequate rather than excellent, while Coca Cola distributor **Arca Continental** reported reasonable volume growth in Mexico and the US, but weaker sales in South America. **Alsea** lost 12.5% while **Arca** shed 7.9%.

A visit to China this month also confirmed what we have known for long, which is that most Chinese enterprises are performing quite adequately, and many are doing well. The issue for the market remains one of investor confidence in the face of an overbearing government which seems to have very little interest in supporting the private sector. Until this perception changes and although profitable opportunities exist, we believe that a substantial rerating of the market is unlikely, although further upside cannot be ruled out in the short term.

All reference to stock performance data is sourced by Aubrey through Bloomberg.

## AVAILABLE SHARE CLASS PRICES

SHARE CLASS	PRICE	ISIN	BLOOMBERG	MANAGEMENT FEE *	ONGOING CHARGES FIGURE	MINIMUM SUBSCRIPTION	MIN. ADDITIONAL SUBSCRIPTION
B Acc GBP	84.61	GB00BNDMH797	SVGEMGA LN	0.75%	1.15%	GBP 5,000	GBP 5,000
B Acc USD	105.30	GB00BNDMH912	SVGEMUA LN	0.75%	1.15%	USD 7,000	USD 7,000

Prices in pence/cents  
Ongoing charges figure (OCF) is based upon the expenses incurred but does not include transaction costs. The transaction costs for 2023 were 0.30%.  
\*Management fee includes Aubrey's fee and excludes ACD fee.

## PLATFORMS

AVIVA, Embark, Fidelity, Hargreaves Lansdown, M&G, Nucleus & Transact

## MARKETING COMMUNICATION



## CONTACTS

### Investment Enquiries

EMAIL	clientservices@aubreycm.co.uk
TELEPHONE	+44 (0)131 226 2083

### Dealing Enquiries

CONTACT	Evelyn Partners Fund Solutions Limited
TELEPHONE	+44 (0)141 222 1150

### Head Office

ADDRESS	Aubrey Capital Management Limited 10 Coates Crescent Edinburgh EH3 7AL
---------	---

## ENVIRONMENTAL, SOCIAL & GOVERNANCE

Aubrey bases its measures for ESG analysis on the United Nations Global Compact. This framework provides us with a foundation for assessing corporate sustainability where we focus our analysis on four themes:

1. Human Rights: Companies should respect the internationally declared human rights laws.
2. Labour: Elimination of discrimination in the workplace as well as all forms of forced labour.
3. Environment: Encourage companies to develop and create initiatives that promote sustainability.
4. Anti-Corruption: Businesses should eliminate corruption in all forms, including bribery.

Signatory of:



## IMPORTANT INFORMATION

This is a marketing communication issued by Aubrey Capital Management Limited which is authorised and regulated by the Financial Conduct Authority. Please refer to the prospectus and the KIID before making any final investment decisions and if you are still unsure, seek independent professional advice. Investors in the Fund are exposed to fluctuations in the Fund's value, which can go down as well as up, and may be subject to significant volatility due to market conditions and changes in foreign exchange rates. Past investment performance is not an indication of future performance. The Fund aims to invest all its assets in emerging market equities which have a higher than average risk when compared to investing in more established markets as investments may be affected by local market conditions. As a result of these risks, you should ensure investment in the Fund is suitable for you.

Aubrey Capital Management has taken reasonable care to ensure the accuracy of this information at the time of publication but it is subject to change without notice and it does not in any way constitute investment advice or an offer or invitation to deal in securities. The Fund is not registered for sale in the United States and is not available to, or for the benefit of, U.S. persons as defined by U.S. securities laws.

MSCI: The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com).

Please click [here](#) to access the Fund's documentation.